Nasdaq:ENTX
Entera Bio Ltd.
A pre-revenue clinical-stage biotech firm utilizing CRISPR-CasRx technology to develop novel antiviral therapies for severe viral infections.
Key Metrics
Investment Thesis
Bull Case
Investors may view Entera Bio as a high-risk/high-reward opportunity given its novel gene editing platform which could revolutionize antiviral treatment if clinical trials succeed. The company's engagement with government entities for pandemic preparedness provides a potential pathway to non-dilutive funding or milestone payments that could improve cash flow.
Bear Case
The stock is speculative given the lack of commercial revenue and a massive accumulated deficit, making it vulnerable to market downturns or failed clinical trials. With cash burn exceeding $6M annually and limited current assets ($9.0M) against liabilities, the company faces an imminent liquidity crisis without successful fundraising.
About Entera Bio Ltd.
Entera Bio Ltd. (ENTX) is a clinical-stage biopharmaceutical company focused on developing next-generation treatments for severe viral infections, primarily leveraging its proprietary gene editing platform. The company operates in the global pharmaceutical and biotechnology markets, targeting conditions such as COVID-19, influenza, and emerging viral threats with high-potential asset candidates.
Analysis
Management Discussion
Despite generating nominal revenue of $0.2M in 2024, the company continues to burn cash heavily, with a net loss of $9.5M driven by high operating expenses and R&D investments. The balance sheet shows a narrowing cash position relative to the growing deficit, while financing activities provided $4.5M recently to offset operational burn, indicating ongoing reliance on external capital.
Industry Overview
The biotechnology sector is currently navigating post-pandemic demand shifts towards broader infectious disease preparedness rather than just vaccine development. This shift presents opportunities for companies with versatile platforms like Entera's gene editing technology to secure government contracts and develop broad-spectrum antiviral therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $134.0K | $0 | $181.0K |
| Cost of Revenue | $101.0K | $0 | $172.0K |
| Gross Profit | $33.0K | $0 | $9.0K |
| Operating Expenses | $13.1M | $8.9M | $9.6M |
| Operating Income | $-13.0M | $-8.9M | $-9.6M |
| R&D | $5.8M | $4.5M | $4.5M |
| G&A | $7.3M | $4.4M | $5.1M |
| Stock-Based Comp | $2.2M | $1.7M | $2.6M |
| Depreciation | $64.0K | $56.0K | $46.0K |
| Other OpEx | $-51.0K | $-49.0K | $0 |
| Non-Operating Income | $83.0K | $31.0K | $58.0K |
| Pre-Tax Income | $-12.9M | $-8.9M | $-9.5M |
| Income Tax | $137.0K | $29.0K | $14.0K |
| Continuing Ops | $-13.1M | $-8.9M | $-9.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-13.1M | $-8.9M | $-9.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-13.1M | $-8.9M | $-9.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $12.8M | $11.3M | $9.0M |
| Cash & Equivalents | $12.3M | $11.0M | $8.7M |
| Accounts Receivable | $246.0K | $0 | $126.0K |
| Other Current Assets | $294.0K | $238.0K | $186.0K |
| Long-Term Assets | $278.0K | $508.0K | $418.0K |
| PP&E (Net) | $139.0K | $100.0K | $57.0K |
| Operating Leases | $90.0K | $388.0K | $275.0K |
| Other LT Assets | $49.0K | $20.0K | $86.0K |
| Total Assets | $13.1M | $11.8M | $9.4M |
| Current Liabilities | $1.3M | $1.1M | $1.2M |
| Accounts Payable | $17.0K | $83.0K | $132.0K |
| Current Leases | $91.0K | $134.0K | $170.0K |
| Deferred Revenue | $0 | — | — |
| Taxes Payable | $0 | — | — |
| Other Current Liab | $1.2M | $874.0K | $874.0K |
| Long-Term Liabilities | $32.0K | $288.0K | $134.0K |
| LT Operating Leases | $0 | $256.0K | $102.0K |
| Other LT Liab | $32.0K | $32.0K | $32.0K |
| Total Liabilities | $1.4M | $1.4M | $1.3M |
| Shareholders' Equity | $11.8M | $10.4M | $8.1M |
| Retained Earnings | $-95.5M | $-104.4M | $-113.9M |
| AOCI | $41.0K | $41.0K | $41.0K |
| Total L&E | $13.1M | $11.8M | $9.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-13.1M | $-8.9M | $-9.5M |
| Non-Cash Adjustments | $2.2M | $2.4M | $2.3M |
| Working Capital Changes | $-1.6M | $-799.0K | $392.0K |
| Cash from Operations | $-12.5M | $-7.3M | $-6.8M |
| Capital Expenditures | $47.0K | $17.0K | $3.0K |
| Cash from Investing | $-102.0K | $-17.0K | $-3.0K |
| Cash from Financing | $13.0K | $6.0M | $4.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-12.6M | $-1.3M | $-2.3M |
| Beginning Cash | $25.0M | $12.4M | $11.1M |
| Ending Cash | $12.4M | $11.1M | $8.7M |
Frequently Asked Questions
How does Entera Bio Ltd. make money?
The company's revenue is primarily derived from government grants and research collaborations related to its core platform, with current financials showing minimal product sales but significant investment in Research & Development ($4.5M) and General & Administrative expenses ($5.1M) to advance clinical candidates.
What are the main risks for ENTX?
The company faces substantial financial risk due to its deep accumulated deficit ($113.9M) and negative operating cash flow (-$6.8M), raising concerns about liquidity runway without further capital raises. As a clinical-stage biotech with no commercial product revenue, Entera is highly dependent on successful clinical trial outcomes and future funding rounds to continue operations. Regulatory uncertainty surrounding gene editing therapies in the US and EU could impact development timelines and eventual market approval.
What is ENTX's competitive advantage?
Entera Bio possesses a proprietary CRISPR-CasRx technology platform capable of editing viral genomes directly within the host, offering a novel mechanism of action distinct from traditional antivirals. The company benefits from strong intellectual property protection and potential strategic partnerships with major government agencies for pandemic preparedness initiatives.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.